
Drug maker AstraZeneca has announced plans to invest 50 billion dollars (£37 billion) in the US over the next five years amid the looming threat of President Donald Trump’s trade tariffs.
The Cambridge-headquartered firm said the investment will fund a new “state-of-the-art” manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world.